MINNEAPOLIS and ATLANTA, April 16, 2026 /PRNewswire/ -- Francis Medical, Inc., a privately held medical device company, today announced the continued expansion of its U.S. commercial launch with the ...
MINNEAPOLIS, March 5, 2026 /PRNewswire/ -- Francis Medical, Inc., a privately held medical device company, announced today the successful completion of the first commercial (non-clinical trial) ...
TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, ...
The VIOLETTE trial, which used OBT-fusion technology for patients with focal ablation of the prostate by microwave needles, released interim results. Investigators of the multicentric, phase 2 ...
The global tumor ablation market is valued at USD 1.04 billion in 2026 and is projected to reach USD 1.8 billion by 2031, ...
—A recent meta-analysis of 35 studies showed that TURP was associated with lower odds of early and persistent LUTS compared with ablation and enucleation. After surgery for benign prostatic ...
A urologist explains how prostate treatments differ in relief, side effects, recovery, and how well they fit individual needs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results